Not yet investigated
What we have so far
The endpoint continuous monitoring made possible, and the first real competitor to HbA1c in forty years.
This star is on the map because the show intends to take the question apart properly — the trials, how it is actually tested, whether the thing sold is the thing studied. That work is not done yet, and nothing here should be read as a conclusion. When the investigation is published it will appear on this page.